Eppendorf SE: conversion to European public limited company

The internationally active life science company Eppendorf, headquartered in Hamburg, Germany, has completed its conversion to the European legal form Societas Europaea (SE) as of October 19, 2021.

"We are convinced that we have taken the right step at the right time with this modern legal form, which is very common in large family-owned companies," said Eva van Pelt and Dr. Peter Fruhstorfer, Co-CEOs of Eppendorf SE. "The company's name as a European public limited company is a clear signal that even more strongly expresses Eppendorf's global corporate culture. In addition, the new legal form shows that Eppendorf is an international company and that national borders play less and less of a role for us."

The company will operate as Eppendorf SE with immediate effect. Picture: © Eppendorf SE

The new company name as Eppendorf SE demonstrates the company's further development into a modern, progressive, and internationally active European company, the CEOs added. Also, it provides important support that will enable Eppendorf to continue its global success course even more effectively, they said.

The conversion into a Societas Europaea will not result in any changes to the company's structure. Management Board and Supervisory Board members continue to work for Eppendorf SE. Eppendorf's Group headquarters will remain in Hamburg, Germany, and the character of an independent familyowned company will be preserved.

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …